About Skincential Sciences
Skincential Sciences, formerly LiquiDx, develops non-invasive diagnostic technologies. The Company's product is the Clearista Refining Pen which delivers a safe and patented solution which through focused exfoliation, smoothes a range of raised and/or pigmented surface imperfections; bumps, discolorations and rough spots on the skin's surface.
Skincential Sciences Patents
Skincential Sciences has filed 1 patent.
Analytical chemistry, Chromatography, Surfactants, Molecular biology, Mass spectrometry
Analytical chemistry, Chromatography, Surfactants, Molecular biology, Mass spectrometry
Latest Skincential Sciences News
Jul 5, 2016
How a new DNA-collecting technology, by way of skin-smoothing products, got the CIA's attention. Magnification: x6000 at 10-cm. wide. Rina Raphael 07.04.166:00 AM When the CIA invested in a skin care brand, some hoped the agency was taking on that particular scourge of beauty terrorism: wrinkles. In fact, it was the CIA's venture capital fund, In-Q-Tel, which invested in Skincential Sciences , a company best known to consumers for its patented skin-smoothing gel Clearista—a popular cosmetic product that’s been hailed by beauty bloggers and dermatologists alike. Clearista Founded in 2010 as a medical diagnostics company, Skincential’s goal was to find a way to release and collect certain biomarkers from human skin. "Your biomarker profile can reflect a number of things—where you’ve been, what you’ve done, who you are," explained Russ Leibovitz, CEO of Skincential Sciences. Just as the microbiome of a person’s gut has become an area of intense interest to researchers ( and even the White House ), the microbiome of the skin can be analyzed to detect everything from chronic skin conditions and cancer to a person’s geographic history . The trouble is that the skin is a notoriously difficult surface to gather biomarkers from. There are three common ways to collect biomarkers from the skin, says Leibovitz: biopsies ("which is very invasive"), skin scraping ("you can accidentally go very deep"), and variations of Scotch tape ("but it can be hard to recover DNA from tape"). During early tests of their biomarker harvesting product, Skincential’s scientists feared that the product would irritate skin. Instead, they discovered just the opposite: Their test subjects enthusiastically approached researchers following test studies. "The response we got from almost every [test subject] who used it was, 'Whoa, this made my skin feel really smooth. Not only is this not irritating, it changed the way my skin feels and reflects light,’" recalled Leibovitz, who compared the product’s gentleness to baby shampoo. "That was an aha moment for us. " The business quickly made a sharp right turn, bottling up its skin-lab potion and marketing it to mature women. But moving into the consumer cosmetics space was a costly proposition, and the investors had to be won over. "This is a business that generally requires a lot of marketing dollars, and we haven’t had those," he said. "We had to do the groundwork. " The investors also knew that creating a medical product would cost tens of millions of dollars through a formal regulatory process that would take three years, at best. "I wouldn't say our investors were skeptical," said Leibovitz, who appealed to investors to give him one year to develop a prototype with investment dollars, "but they wanted to see what we were doing at every step. " Through word of mouth and cold-sending products to beauty editors and influential beauty bloggers, Clearista gathered a loyal and rapidly growing following of fans who lauded the product for its ability to minimize the appearance of fine lines, smooth rough patches, and brighten skin spots. As Leibovitz explains, it's like taking skin texture from linen to silk. They began selling exclusively on the web, but then found that when products were used more aggressively by professionals, the results were far more successful. And so they branched out into medical spas. Dermatologists can increase the product's intensity with amount applied and time spent scrubbing. Penny Johnson, a licensed medical aesthetician from the O’Connell Dermatology practice in Torrance, Calif., recommends Clearista to clientele looking for tailored, noninvasive treatments. "There's a whole combination of things that [Clearista] can do that’s a lot more in detail versus the competition," she said of the product, used for both skin abrasion removal and antiaging facial treatments. "It lets you customize for each specific person," she explained, noting that customers don't want "a cookie-cutter deal," but rather something that's specifically beneficial to them. "No one person is the same. " It's an opportunity Skincential Sciences is acutely aware of. While the cosmetic industry has made significant strides in science, each year brings new levels reached in terms of clinical results. And consumers are noticing, explained Karen Grant, global beauty industry analyst of the NPD Group. "Today, brands offering the efficacy of scientific research and those offering the safety of natural (or a combination of the two) are at the forefront of the market in driving trends and growth," Grant said of the U.S. beauty market, which according to NPD's most recent estimate, generated sales of $48 billion in 2014. Brands identified as clinical/cosmeceutical grew 10% in facial skin care sales over the previous year, while the overall prestige facial skin care market grew by only 1%. After registering their patents in 2013 and further optimizing their product, they pivoted to focusing entirely on skin care. "We came to realize the power of what we had created, and that while it was now great for something diagnostic, it was also great to just apply directly to the skin. " But product sales are only skin deep for Skincential Sciences. More than anything, the company aims to change the way skin care markets, driving a more scientific approach to it all. Moving forward, Skincential plans on "dramatically" expanding their line, launching new products based on the same chemistry but using different formulations, such as serums for sensitive skin. "We have a product that in the hands of someone who had a bigger budget and already had channels could be selling a lot more without really even changing the product," Leibovitz said. At the same time, because the original IP is protected, Skincential could be a licensing gold mine. "A skin care company might look at this a little more like a medical product," said Liebovitz, "and say, "We can build 20 products around this. '" Newsletter Get the latest Fast Company stories delivered to your inbox daily. Send I'd also like to receive special Fast Company offers Must Reads
Skincential Sciences Frequently Asked Questions (FAQ)
Where is Skincential Sciences's headquarters?
Skincential Sciences's headquarters is located at 8070 La Jolla Shores Drive, La Jolla.
What is Skincential Sciences's latest funding round?
Skincential Sciences's latest funding round is Unattributed VC.
How much did Skincential Sciences raise?
Skincential Sciences raised a total of $300K.
Who are the investors of Skincential Sciences?
Investors of Skincential Sciences include In-Q-Tel and Mercury Fund.
Who are Skincential Sciences's competitors?
Competitors of Skincential Sciences include EPIC Research & Diagnostics and 4 more.
Compare Skincential Sciences to Competitors
Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
IntraTherm is focused on continuous improvement of the medical device industry through the introduction of processes and products that aid surgeons and patients in their fight against cancer. The company's product is designed to complement surgery by sterilizing the site of surgery via a controllable and predictable thermal ablation device, with less than minimal short term, and without long term side effects.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Biocom works to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs, and create value-driven purchasing programs.
Harvard Bioscience is a global developer and manufacturer in the life sciences sector, focusing on specialized products, primarily apparatus and scientific instruments. The company's main offerings include a broad range of equipment and instruments used to advance life science research, such as spectrophotometers, amino acid analyzers, and electrophysiology systems. Harvard Bioscience primarily sells to the pharmaceutical and biotechnology industries, as well as universities and government laboratories worldwide. It is based in Holliston, Massachusetts.
Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.